JP2023533807A5 - - Google Patents

Info

Publication number
JP2023533807A5
JP2023533807A5 JP2023502631A JP2023502631A JP2023533807A5 JP 2023533807 A5 JP2023533807 A5 JP 2023533807A5 JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023533807 A5 JP2023533807 A5 JP 2023533807A5
Authority
JP
Japan
Prior art keywords
methyl
pyridine
dihydro
piperazine
isoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023502631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/069294 external-priority patent/WO2022013136A1/en
Publication of JP2023533807A publication Critical patent/JP2023533807A/ja
Publication of JP2023533807A5 publication Critical patent/JP2023533807A5/ja
Ceased legal-status Critical Current

Links

JP2023502631A 2020-07-14 2021-07-12 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 Ceased JP2023533807A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/101904 2020-07-14
CN2020101904 2020-07-14
CN2021094138 2021-05-17
CNPCT/CN2021/094138 2021-05-17
PCT/EP2021/069294 WO2022013136A1 (en) 2020-07-14 2021-07-12 Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
JP2023533807A JP2023533807A (ja) 2023-08-04
JP2023533807A5 true JP2023533807A5 (cg-RX-API-DMAC10.html) 2024-07-22

Family

ID=77126791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502631A Ceased JP2023533807A (ja) 2020-07-14 2021-07-12 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Country Status (6)

Country Link
US (1) US20240317735A1 (cg-RX-API-DMAC10.html)
EP (1) EP4182032A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023533807A (cg-RX-API-DMAC10.html)
CN (1) CN115835910A (cg-RX-API-DMAC10.html)
TW (1) TW202216711A (cg-RX-API-DMAC10.html)
WO (1) WO2022013136A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021325927A1 (en) * 2020-08-14 2023-02-23 Minerva Neurosciences, Inc. Condensed azacycles as sigma ligand compounds and uses thereof
PE20250401A1 (es) * 2021-09-24 2025-02-11 Hoffmann La Roche Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias
CN120230100B (zh) * 2025-05-30 2025-09-05 中国药科大学 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
EP4059934B1 (en) * 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
WO2018218197A2 (en) * 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
JP7287967B2 (ja) * 2017-12-20 2023-06-06 ブリストル-マイヤーズ スクイブ カンパニー Tlr阻害剤として有効なアミノインドール化合物
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
US12157746B2 (en) 2018-06-05 2024-12-03 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
US20220340597A1 (en) * 2019-04-09 2022-10-27 Hoffmann-La Roche Inc. Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Similar Documents

Publication Publication Date Title
JP2024502433A5 (cg-RX-API-DMAC10.html)
US12331056B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
EP3630770B1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
JP2022504936A5 (cg-RX-API-DMAC10.html)
JP2021527041A5 (cg-RX-API-DMAC10.html)
JP2023549341A (ja) Brm標的化化合物及び関連する使用方法
JP2022543689A (ja) Shp2阻害剤
JP2022527588A5 (cg-RX-API-DMAC10.html)
RU2018133279A (ru) Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB)
JP2023539663A (ja) 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
IL256324A (en) 1, 4-substituted piperidine derivatives
JP2014506929A5 (cg-RX-API-DMAC10.html)
JP2017524702A (ja) CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
JP2024540912A (ja) 癌の治療における使用のためのヘテロ環式化合物
CA3098291A1 (en) Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease
JP2023533807A (ja) 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物
TW202330525A (zh) 稠環取代的六員雜環化合物及其製法和用途
JP2022508523A5 (cg-RX-API-DMAC10.html)
JP2024534567A5 (cg-RX-API-DMAC10.html)
TH2401004994A (th) อิมิดาโซลมาโครไซเคิลสำหรับการบำบัดของโรคภูมิต้านต่อตนเอง
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
RU2024111196A (ru) Соединения пиразоло[3,4-b]пиридина для лечения аутоиммунного заболевания
RU2025127920A (ru) Соединения пиридазина, их получение и пути их терапевтического применения
RU2025108617A (ru) Гетероциклические производные в качестве ингибиторов янус-киназы
NZ768960A (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease